Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 116

1.

Protein tyrosine phosphatase kappa (PTPRK) is a negative regulator of adhesion and invasion of breast cancer cells, and associates with poor prognosis of breast cancer.

Sun PH, Ye L, Mason MD, Jiang WG.

J Cancer Res Clin Oncol. 2013 Jul;139(7):1129-39. doi: 10.1007/s00432-013-1421-5. Epub 2013 Apr 4.

PMID:
23552869
2.

Protein tyrosine phosphatase µ (PTP µ or PTPRM), a negative regulator of proliferation and invasion of breast cancer cells, is associated with disease prognosis.

Sun PH, Ye L, Mason MD, Jiang WG.

PLoS One. 2012;7(11):e50183. doi: 10.1371/journal.pone.0050183. Epub 2012 Nov 20.

3.

Receptor-like protein tyrosine phosphatase κ negatively regulates the apoptosis of prostate cancer cells via the JNK pathway.

Sun PH, Ye L, Mason MD, Jiang WG.

Int J Oncol. 2013 Nov;43(5):1560-8. doi: 10.3892/ijo.2013.2082. Epub 2013 Aug 29.

PMID:
24002526
4.

High levels of γ-glutamyl hydrolase (GGH) are associated with poor prognosis and unfavorable clinical outcomes in invasive breast cancer.

Shubbar E, Helou K, Kovács A, Nemes S, Hajizadeh S, Enerbäck C, Einbeigi Z.

BMC Cancer. 2013 Feb 1;13:47. doi: 10.1186/1471-2407-13-47.

5.

Receptor-type tyrosine-protein phosphatase κ directly targets STAT3 activation for tumor suppression in nasal NK/T-cell lymphoma.

Chen YW, Guo T, Shen L, Wong KY, Tao Q, Choi WW, Au-Yeung RK, Chan YP, Wong ML, Tang JC, Liu WP, Li GD, Shimizu N, Loong F, Tse E, Kwong YL, Srivastava G.

Blood. 2015 Mar 5;125(10):1589-600. doi: 10.1182/blood-2014-07-588970. Epub 2015 Jan 22.

6.

Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion.

Freitas VM, do Amaral JB, Silva TA, Santos ES, Mangone FR, Pinheiro Jde J, Jaeger RG, Nagai MA, Machado-Santelli GM.

Mol Cancer. 2013 Jan 5;12:2. doi: 10.1186/1476-4598-12-2.

7.
8.

Capillary morphogenesis gene 2 inhibits growth of breast cancer cells and is inversely correlated with the disease progression and prognosis.

Ye L, Sun PH, Malik MF, Mason MD, Jiang WG.

J Cancer Res Clin Oncol. 2014 Jun;140(6):957-67. doi: 10.1007/s00432-014-1650-2. Epub 2014 Mar 26.

PMID:
24667935
9.

Expression of Egfl7 correlates with low-grade invasive lesions in human breast cancer.

Philippin-Lauridant G, Baranzelli MC, Samson C, Fournier C, Pinte S, Mattot V, Bonneterre J, Soncin F.

Int J Oncol. 2013 Apr;42(4):1367-75. doi: 10.3892/ijo.2013.1820. Epub 2013 Feb 8.

PMID:
23404186
10.

Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.

Powe DG, Voss MJ, Habashy HO, Zänker KS, Green AR, Ellis IO, Entschladen F.

Breast Cancer Res Treat. 2011 Nov;130(2):457-63. doi: 10.1007/s10549-011-1371-z. Epub 2011 Feb 6.

PMID:
21298476
11.

The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.

Zia MK, Rmali KA, Watkins G, Mansel RE, Jiang WG.

Int J Mol Med. 2007 Oct;20(4):605-11.

PMID:
17786294
12.

Tumor derived mutations of protein tyrosine phosphatase receptor type k affect its function and alter sensitivity to chemotherapeutics in glioma.

Agarwal S, Al-Keilani MS, Alqudah MA, Sibenaller ZA, Ryken TC, Assem M.

PLoS One. 2013 May 16;8(5):e62852. doi: 10.1371/journal.pone.0062852. Print 2013.

13.

Role of MRE11 in cell proliferation, tumor invasion, and DNA repair in breast cancer.

Yuan SS, Hou MF, Hsieh YC, Huang CY, Lee YC, Chen YJ, Lo S.

J Natl Cancer Inst. 2012 Oct 3;104(19):1485-502. doi: 10.1093/jnci/djs355. Epub 2012 Aug 22.

14.

Determination of HER2 phosphorylation at tyrosine 1221/1222 improves prediction of poor survival for breast cancer patients with hormone receptor-positive tumors.

Frogne T, Laenkholm AV, Lyng MB, Henriksen KL, Lykkesfeldt AE.

Breast Cancer Res. 2009;11(1):R11. doi: 10.1186/bcr2230. Epub 2009 Feb 24.

15.

Down-regulation of the TGF-beta target gene, PTPRK, by the Epstein-Barr virus encoded EBNA1 contributes to the growth and survival of Hodgkin lymphoma cells.

Flavell JR, Baumforth KR, Wood VH, Davies GL, Wei W, Reynolds GM, Morgan S, Boyce A, Kelly GL, Young LS, Murray PG.

Blood. 2008 Jan 1;111(1):292-301. Epub 2007 Aug 24.

16.

Expression of membrane type-1 matrix metalloproteinase, MT1-MMP in human breast cancer and its impact on invasiveness of breast cancer cells.

Jiang WG, Davies G, Martin TA, Parr C, Watkins G, Mason MD, Mansel RE.

Int J Mol Med. 2006 Apr;17(4):583-90.

PMID:
16525713
17.

High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer.

Salhab M, Patani N, Jiang W, Mokbel K.

Breast Cancer. 2012 Apr;19(2):153-60. doi: 10.1007/s12282-010-0228-3. Epub 2010 Oct 23.

PMID:
20972741
18.

Differential expression of histone deacetylases HDAC1, 2 and 3 in human breast cancer--overexpression of HDAC2 and HDAC3 is associated with clinicopathological indicators of disease progression.

Müller BM, Jana L, Kasajima A, Lehmann A, Prinzler J, Budczies J, Winzer KJ, Dietel M, Weichert W, Denkert C.

BMC Cancer. 2013 Apr 30;13:215. doi: 10.1186/1471-2407-13-215.

19.

Distinctive role of SIRT1 expression on tumor invasion and metastasis in breast cancer by molecular subtype.

Chung YR, Kim H, Park SY, Park IA, Jang JJ, Choe JY, Jung YY, Im SA, Moon HG, Lee KH, Suh KJ, Kim TY, Noh DY, Han W, Ryu HS.

Hum Pathol. 2015 Jul;46(7):1027-35. doi: 10.1016/j.humpath.2015.03.015. Epub 2015 Apr 15.

PMID:
26004371
20.

Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.

Rezano A, Kuwahara K, Yamamoto-Ibusuki M, Kitabatake M, Moolthiya P, Phimsen S, Suda T, Tone S, Yamamoto Y, Iwase H, Sakaguchi N.

BMC Cancer. 2013 Dec 1;13:562. doi: 10.1186/1471-2407-13-562.

Items per page

Supplemental Content

Write to the Help Desk